The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system
Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for live...
Saved in:
Published in | Scientific reports Vol. 15; no. 1; pp. 20090 - 11 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
19.06.2025
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes. |
---|---|
AbstractList | Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes. Abstract Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes. Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP-albumin-lymphocyte (CALLY) index-a composite indicator of systemic inflammation, nutritional status, and immune function-as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan-Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model's performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39-0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572-0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes.Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP-albumin-lymphocyte (CALLY) index-a composite indicator of systemic inflammation, nutritional status, and immune function-as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan-Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model's performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39-0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572-0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes. Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the CRP–albumin–lymphocyte (CALLY) index—a composite indicator of systemic inflammation, nutritional status, and immune function—as a prognostic tool for liver cancer, comparing its predictive utility to the established TNM staging system. A retrospective cohort of 388 patients with histologically confirmed liver cancer was analyzed using data from the Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) database. Kaplan–Meier survival analysis, restricted cubic spline (RCS) functions, and multivariate Cox regression models were utilized to determine the prognostic significance of the CALLY index. A nomogram was constructed incorporating the CALLY index, age, and TNM stage to estimate 1-, 2-, 3-year OS. The model’s performance was benchmarked against the TNM staging system using time-dependent receiver operating characteristic (ROC) curves and Decision curve analysis (DCA). Multivariate Cox regression analysis demonstrated that the CALLY index was independently associated with OS in patients with liver cancer [Hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.39–0.83, P =0.003]. The prognostic value of the CALLY index was superior to that of the TNM staging system (C-index = 0.621, 95% CI 0.572–0.669, P < 0.001). Compared with the traditional TNM staging system, the prognostic nomogram incorporating the CALLY index, age, and TNM stage demonstrated higher accuracy in predicting 1-, 2-, and 3-year OS in patients with liver cancer (1-year: 0.705 vs. 0.644; 2-year: 0.698 vs. 0.66; 3-year: 0.6499 vs. 0.6079). The CALLY index is a robust prognostic biomarker for liver cancer, offering enhanced predictive accuracy over traditional staging methods. Its incorporation into a predictive nomogram may facilitate personalized treatment strategies, ultimately improving patient outcomes. |
ArticleNumber | 20090 |
Author | Yin, Bing Li, Xiang-Rui Liu, Xiao-Yue Shi, Han-Ping Bu, Zhao-Ting Zhao, Hong |
Author_xml | – sequence: 1 givenname: Hong surname: Zhao fullname: Zhao, Hong organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University – sequence: 2 givenname: Bing surname: Yin fullname: Yin, Bing organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University – sequence: 3 givenname: Xiang-Rui surname: Li fullname: Li, Xiang-Rui organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University – sequence: 4 givenname: Xiao-Yue surname: Liu fullname: Liu, Xiao-Yue organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University – sequence: 5 givenname: Zhao-Ting surname: Bu fullname: Bu, Zhao-Ting organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University – sequence: 6 givenname: Han-Ping surname: Shi fullname: Shi, Han-Ping email: shihp@ccmu.edu.cn organization: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, Laboratory for Clinical Medicine, Capital Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40537551$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks2O0zAQxyO0iF2WfQEOKBIXLgF_TWIfUbXASsuHUO-Wa0_SVIld7KSinHgH3pAnwW2XBXHAlxmNfjPjv_1_XJz54LEonlLykhIuXyVBQcmKMKgIVxKq5kFxwYiAinHGzv7Kz4urlDYkH2BKUPWoOBcEeANAL4pvyzWWi8-ffn7_YYbVPPY-Z8N-3K6D3U9Y9t7h13Ibw653mEr0a-MtukOl8yFNvS13ZpgPYDn0O4ylPQA5hHFrYianUE55x_LD-zJNput9V6Z9mnB8UjxszZDw6i5eFss318vFu-r249ubxevbygoup6qVHFpiiALHsRWtcUgaI4SUitq6Nc2KWmyIQ2CSNYZIAIWSSueUddbwy-LmNNYFs9Hb2I8m7nUwvT4WQuy0iVnHgHolpQULXNIaBCGtAmhrySi0K2Gks3nWi9OsLP_LjGnSY58sDoPxGOak82uzmivS8Iw-_wfdhDn6LPRICVmDgkw9u6Pm1Yju_nq_PygD7ATYGFKK2N4jlOiDEfTJCDobQR-NoJvcxE9NKcO-w_hn93-6fgEeQ7c1 |
Cites_doi | 10.3389/fimmu.2023.1131496 10.1016/j.ccell.2023.02.016 10.3350/cmh.2022.0316 10.1007/s00520-023-07997-9 10.3389/fmed.2025.1543665 10.1007/s12072-015-9665-6 10.1111/liv.15115 10.1016/j.nut.2023.112191 10.1016/j.jhep.2018.12.001 10.1007/s00595-016-1433-2 10.1016/j.jhep.2022.08.021 10.1016/j.hpb.2021.06.414 10.1038/s41568-021-00383-9 10.1038/s41576-022-00553-x 10.1016/j.jhep.2022.06.012 10.1016/j.intimp.2021.108220 10.3389/fonc.2020.00171 10.21873/anticanres.16572 10.1007/s11695-021-05237-9 10.1016/j.bbcan.2019.188314 10.1016/j.suronc.2023.101911 10.17998/jlc.20.2.106 10.3390/cancers13195018 10.3389/fimmu.2022.1002652 10.1186/s12943-019-1047-6 10.1038/nrdp.2016.18 10.1007/s12029-023-01008-0 10.1016/j.hpb.2023.08.012 10.1056/NEJMra1713263 10.1186/s13046-023-02609-0 10.1055/s-0038-1676806 10.1016/j.jhep.2022.02.032 10.1111/acel.13512 10.1002/ags3.12637 10.1038/s41571-023-00734-5 10.1021/jacs.3c05052 10.1038/nature16969 |
ContentType | Journal Article |
Copyright | The Author(s) 2025 2025. The Author(s). Copyright Nature Publishing Group 2025 |
Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: Copyright Nature Publishing Group 2025 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA |
DOI | 10.1038/s41598-025-03985-7 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Science Database Biological Science Database (Proquest) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central - New (Subscription) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_b88c5c538165400f955f68215fb4a8dc 40537551 10_1038_s41598_025_03985_7 |
Genre | Journal Article Comparative Study |
GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AAYXX CITATION CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7XB 88A 8FK K9. M48 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO |
ID | FETCH-LOGICAL-c438t-f835f0a095d3ef4fade07a448891c6fa7b1ce70de52827a08559e818dd9cdca3 |
IEDL.DBID | C6C |
ISSN | 2045-2322 |
IngestDate | Wed Aug 27 01:29:07 EDT 2025 Fri Jul 11 17:03:44 EDT 2025 Sat Aug 23 14:09:59 EDT 2025 Mon Jul 21 06:06:24 EDT 2025 Thu Jul 03 08:44:05 EDT 2025 Fri Jun 20 01:11:51 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Liver cancer The CALLY index Survival Nomogram |
Language | English |
License | 2025. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c438t-f835f0a095d3ef4fade07a448891c6fa7b1ce70de52827a08559e818dd9cdca3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.nature.com/articles/s41598-025-03985-7 |
PMID | 40537551 |
PQID | 3222486595 |
PQPubID | 2041939 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b88c5c538165400f955f68215fb4a8dc proquest_miscellaneous_3222639073 proquest_journals_3222486595 pubmed_primary_40537551 crossref_primary_10_1038_s41598_025_03985_7 springer_journals_10_1038_s41598_025_03985_7 |
PublicationCentury | 2000 |
PublicationDate | 2025-06-19 |
PublicationDateYYYYMMDD | 2025-06-19 |
PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-19 day: 19 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2025 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Z Liu (3985_CR3) 2019; 70 3985_CR36 BS Kim (3985_CR30) 2020; 20 H Rumgay (3985_CR4) 2022; 77 Q Wang (3985_CR32) 2023; 2 H Xu (3985_CR34) 2022; 1 XY Liu (3985_CR14) 2023; 31 K Furukawa (3985_CR12) 2023; 47 X Li (3985_CR8) 2021; 21 M Zhou (3985_CR33) 2023; 2 T Aoyama (3985_CR19) 2023; 43 S Mohammed (3985_CR44) 2021; 20 C Lu (3985_CR26) 2019; 18 P Dasgupta (3985_CR6) 2020; 10 H Zhang (3985_CR15) 2023; 116 3985_CR18 M Peiseler (3985_CR43) 2022; 77 JM Argilés (3985_CR23) 2023; 20 JM Llovet (3985_CR1) 2016; 2 WT Dou (3985_CR11) 2023; 145 SQ Lang (3985_CR17) 2025; 12 S Choi (3985_CR5) 2023; 29 A Villanueva (3985_CR2) 2019; 380 K Yoshimatsu (3985_CR24) 2017; 44 D Anwanwan (3985_CR7) 2020; 1873 BI Carr (3985_CR10) 2021; 18 Z Seferbekova (3985_CR22) 2023; 24 R Spinella (3985_CR39) 2016; 10 YY Wang (3985_CR35) 2003; 66 J Cui (3985_CR31) 2023; 2 M Tsunematsu (3985_CR20) 2023; 7 KE de Visser (3985_CR21) 2023; 41 MB Schoenberg (3985_CR27) 2021; 101 X Fu (3985_CR40) 2022; 42 YM Yang (3985_CR42) 2019; 39 M Barsch (3985_CR25) 2022; 77 YP Mendoza (3985_CR38) 2021; 31 BI Carr (3985_CR9) 2018; 15 C Dix (3985_CR45) 2022; 13 Y Iseki (3985_CR29) 2017; 47 Y Liu (3985_CR41) 2023; 42 S Omiya (3985_CR37) 2023; 25 M Yang (3985_CR13) 2023; 14 H Iida (3985_CR16) 2022; 24 C Ma (3985_CR28) 2016; 531 |
References_xml | – volume: 14 start-page: 1131496 year: 2023 ident: 3985_CR13 publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1131496 – volume: 2 issue: 1 year: 2023 ident: 3985_CR33 publication-title: Precis. Nutr. – volume: 41 start-page: 374 issue: 3 year: 2023 ident: 3985_CR21 publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.02.016 – volume: 29 start-page: 433 issue: 2 year: 2023 ident: 3985_CR5 publication-title: Clin. Mol. Hepatol. doi: 10.3350/cmh.2022.0316 – volume: 31 start-page: 533 issue: 9 year: 2023 ident: 3985_CR14 publication-title: Support Care Cancer. doi: 10.1007/s00520-023-07997-9 – volume: 12 start-page: 1543665 year: 2025 ident: 3985_CR17 publication-title: Front. Med. (Lausanne). doi: 10.3389/fmed.2025.1543665 – volume: 10 start-page: 124 issue: 1 year: 2016 ident: 3985_CR39 publication-title: Hepatol. Int. doi: 10.1007/s12072-015-9665-6 – volume: 2 issue: 1 year: 2023 ident: 3985_CR32 publication-title: Precis. Nutr. – volume: 42 start-page: 696 issue: 3 year: 2022 ident: 3985_CR40 publication-title: Liver Int. doi: 10.1111/liv.15115 – volume: 116 year: 2023 ident: 3985_CR15 publication-title: Nutrition doi: 10.1016/j.nut.2023.112191 – volume: 70 start-page: 674 issue: 4 year: 2019 ident: 3985_CR3 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2018.12.001 – volume: 47 start-page: 743 issue: 6 year: 2017 ident: 3985_CR29 publication-title: Surg. Today. doi: 10.1007/s00595-016-1433-2 – volume: 77 start-page: 1598 issue: 6 year: 2022 ident: 3985_CR4 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2022.08.021 – volume: 66 start-page: 593 issue: 10 year: 2003 ident: 3985_CR35 publication-title: J. Chin. Med. Assoc. – volume: 18 start-page: 1626 issue: 2 year: 2021 ident: 3985_CR10 publication-title: Clin. Pract. (Lond). – volume: 24 start-page: 101 issue: 1 year: 2022 ident: 3985_CR16 publication-title: HPB (Oxford). doi: 10.1016/j.hpb.2021.06.414 – volume: 21 start-page: 541 issue: 9 year: 2021 ident: 3985_CR8 publication-title: Nat. Rev. Cancer. doi: 10.1038/s41568-021-00383-9 – volume: 24 start-page: 295 issue: 5 year: 2023 ident: 3985_CR22 publication-title: Nat. Rev. Genet. doi: 10.1038/s41576-022-00553-x – volume: 77 start-page: 1136 issue: 4 year: 2022 ident: 3985_CR43 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2022.06.012 – volume: 101 issue: Pt A year: 2021 ident: 3985_CR27 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2021.108220 – volume: 10 start-page: 171 year: 2020 ident: 3985_CR6 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00171 – volume: 43 start-page: 3849 issue: 9 year: 2023 ident: 3985_CR19 publication-title: Anticancer Res. doi: 10.21873/anticanres.16572 – volume: 31 start-page: 2817 issue: 6 year: 2021 ident: 3985_CR38 publication-title: Obes. Surg. doi: 10.1007/s11695-021-05237-9 – volume: 44 start-page: 906 issue: 10 year: 2017 ident: 3985_CR24 publication-title: Gan To Kagaku Ryoho – volume: 1873 issue: 1 year: 2020 ident: 3985_CR7 publication-title: Biochim. Biophys. Acta Rev. Cancer. doi: 10.1016/j.bbcan.2019.188314 – volume: 47 year: 2023 ident: 3985_CR12 publication-title: Surg. Oncol. doi: 10.1016/j.suronc.2023.101911 – volume: 20 start-page: 106 issue: 2 year: 2020 ident: 3985_CR30 publication-title: J. Liver Cancer. doi: 10.17998/jlc.20.2.106 – ident: 3985_CR18 doi: 10.3390/cancers13195018 – volume: 13 start-page: 1002652 year: 2022 ident: 3985_CR45 publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.1002652 – volume: 1 issue: 2 year: 2022 ident: 3985_CR34 publication-title: Precis. Nutr. – volume: 18 start-page: 130 issue: 1 year: 2019 ident: 3985_CR26 publication-title: Mol. Cancer. doi: 10.1186/s12943-019-1047-6 – volume: 2 start-page: 16018 year: 2016 ident: 3985_CR1 publication-title: Nat. Rev. Dis. Primers. doi: 10.1038/nrdp.2016.18 – ident: 3985_CR36 doi: 10.1007/s12029-023-01008-0 – volume: 25 start-page: 1555 issue: 12 year: 2023 ident: 3985_CR37 publication-title: HPB (Oxford). doi: 10.1016/j.hpb.2023.08.012 – volume: 380 start-page: 1450 issue: 15 year: 2019 ident: 3985_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1713263 – volume: 42 start-page: 38 issue: 1 year: 2023 ident: 3985_CR41 publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-023-02609-0 – volume: 39 start-page: 26 issue: 1 year: 2019 ident: 3985_CR42 publication-title: Semin. Liver Dis. doi: 10.1055/s-0038-1676806 – volume: 15 start-page: 625 issue: 1 year: 2018 ident: 3985_CR9 publication-title: Clin. Pract. (Lond) – volume: 77 start-page: 397 issue: 2 year: 2022 ident: 3985_CR25 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2022.02.032 – volume: 20 issue: 12 year: 2021 ident: 3985_CR44 publication-title: Aging Cell doi: 10.1111/acel.13512 – volume: 7 start-page: 503 issue: 3 year: 2023 ident: 3985_CR20 publication-title: Ann. Gastroenterol. Surg. doi: 10.1002/ags3.12637 – volume: 20 start-page: 250 issue: 4 year: 2023 ident: 3985_CR23 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-023-00734-5 – volume: 145 start-page: 17377 issue: 31 year: 2023 ident: 3985_CR11 publication-title: J. Am. Chem. Soc. doi: 10.1021/jacs.3c05052 – volume: 531 start-page: 253 issue: 7593 year: 2016 ident: 3985_CR28 publication-title: Nature doi: 10.1038/nature16969 – volume: 2 issue: 1 year: 2023 ident: 3985_CR31 publication-title: Precis. Nutr. |
SSID | ssj0000529419 |
Score | 2.4499633 |
Snippet | Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the... Abstract Reliable biomarkers are critical for improving overall survival (OS) and guiding therapeutic strategies in liver cancer. This study evaluated the... |
SourceID | doaj proquest pubmed crossref springer |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 20090 |
SubjectTerms | 631/67 692/53 692/700 Adult Aged Albumin Biomarkers Biomarkers, Tumor - blood C-Reactive Protein - analysis C-Reactive Protein - metabolism Cancer Female Humanities and Social Sciences Humans Immune response Kaplan-Meier Estimate Liver cancer Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - pathology Lymphocytes Lymphocytes - metabolism Male Middle Aged multidisciplinary Neoplasm Staging Nomogram Nomograms Nutrition Nutritional status Patients Prognosis Regression analysis Retrospective Studies ROC Curve Science Science (multidisciplinary) Serum Albumin - analysis Serum Albumin - metabolism Survival Survival analysis The CALLY index |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBYhEOiltOmf26So0FsqIluyLB2T0BAKCSVsITch64cWgjd0ncPmlHfoG_ZJMiN5Nylt6aUnG3sQkmak-cSMviHkvWp0cIIn1omgmVTaMVf7nsWee62C4iGXezs9Uydf5KeL9uJBqS_MCSv0wGXi9nutfetbjG8BuODJtG1SGhxV6qXTwePuCz7vwWGqsHo3RtZmuiXDhd5fgKfC22RNy7gwumXdL54oE_b_CWX-FiHNjuf4CXk8IUZ6UHr6lGzEYZtslRqSy2fkBhRNj84__7z9kVONvw3wdrkEJc39cow00yHS6cLdgsbha4754xfMsYNGKRJ-oyC9xCQN6lEAHlN2Oh3nFFAinZ2dUoCSWNSIFv7n52R2_HF2dMKmggrMS6FHlgBuJe4AVQURk0wuRN45OKBpU3uVXNfXPnY8xBYOYp3DFDYTwaOHYHzwTrwgm8N8iK8INSLVjRNSG-6kiqYXwrhkJNJ_AWLzFdlbza29KrQZNoe7hbZFExY0YbMmbFeRQ5z-tSRSXucPYAh2MgT7L0OoyM5KeXZahwuLcSSpkTOxIu_Wv2EFYVjEDXF-XWQAp8FeV5GXRenrnkikuwFQWZEPKyu4b_zvA3r9Pwb0hjxqsrkqVpsdsjl-v467gIDG_m029jtwZQH1 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKu-0BRmJG1h11o5jn6pSUVVIrRBapL1Zjh-AVCWlmx62J_4D_5Bfwozj3QrxOCVKRo7jGdufPeNvCHmlZjo4wRNrRdBMKu2Yq33HYse9VkHxkNO9nZ6pk0_y_aJZlA23ZQmrXI-JeaAOg8c98n30CEiN7HcHF98YZo1C72pJoXGb3EHqMgzpahftZo8FvViyNuWsDBd6fwnzFZ4pmzWMC6Mb1v42H2Xa_r9hzT_8pHn6Od4m9wtupIeToh-QW7F_SO5OmSRXj8g1qJseffzw8_uPHHD8tYe78xWoavCrMdJMikjLsbsljf2X7PnHJxhpB4VSpP1GQXqOoRrUowBcSow6HQcKWJHOz04pAEpMbUQnFujHZH78bn50wkpaBeal0CNLALoSd4CtgohJJhcibx0s07SpvUqu7WofWx5iA8ux1mEgm4kwr4dgfPBOPCFb_dDHZ4QakeqZE1Ib7qSKphPCuGQkkoABbvMVeb1uW3sxkWfY7PQW2k6asKAJmzVh24q8xebfSCLxdX4wXH62pR_ZTmvf-AbdnYA1eTJNk5QG3JI66XSAT-6tlWdLb1zaG9upyMvNa-hH6BxxfRyuJhlAazDiVeTppPRNTSSS3gC0rMibtRXcFP7vH9r5f112yb1ZNkTFarNHtsbLq_gcEM7Yvchm_AsBx_oB priority: 102 providerName: ProQuest |
Title | The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system |
URI | https://link.springer.com/article/10.1038/s41598-025-03985-7 https://www.ncbi.nlm.nih.gov/pubmed/40537551 https://www.proquest.com/docview/3222486595 https://www.proquest.com/docview/3222639073 https://doaj.org/article/b88c5c538165400f955f68215fb4a8dc |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB71ISQuiDeBsjISN7BIYsexj9tVq2qlrqqySHuzHD-gUpWgbnpYTvwH_iG_hLGTXYQoB06JnInjeGzPZ8_4M8BbUUpnWB5ozZykXEhDTWEb6pvcSuFE7tJxb-cLcfaJz1fVag_K7V6YFLSfKC3TML2NDvuwRkMTN4OVFc2ZkhWt9-EwUrfHVj0Ts926SvRc8UKN-2NyJu949Q8blKj678KXf_lGk8k5fQgPRqxIpkPpHsGebx_DveH0yM0T-IYqJrPLi5_ff6Qg46sW7643qJ7ObnpPEhEiGbfarYlvvyRvf0yJ0XWYKYlU31GQXMfwDGKjAF7GuHTSdwTxIVkuzgmCyHicERmYn5_C8vRkOTuj41EK1HImexoQaIXcIJ5yzAcejPN5bXBqJlVhRTB1U1hf585XOAWrTQxeUx5tuXPKOmvYMzhou9a_AKJYKErDuFS54cKrhjFlguKR-Auxms3g3bZu9deBMEMnRzeTetCERk3opAldZ3Acq38nGcmuU0J381mPyteNlLayVXRxIr7Mg6qqICRildBwIx1-8mirPD32wLWOHiQuI1tiBm92j7HvRIeIaX13O8ggQsNRLoPng9J3JeGR6AbhZAbvt63gd-b__qGX_yf-Cu6XqWEKWqgjOOhvbv1rRDl9M4H9elVP4HA6nX-c4_X4ZHFxOUmNfZJWDn4BStH83w |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVoheEL_tQgEjwQmsJrGT2AeEaGm1pd1VVS1Sb5bjH0CqktLdCi0n3oHn4KV4EmacZCvEz62nRMnIcTwz9jee8Qwhz4pMOsOTwEruJBOFNMyktmK-SqwsXJG4WO5tPClG78W7k_xkhfzoz8JgWGU_J8aJ2jUW98i30CMgJGa_e332mWHVKPSu9iU0WrE48IsvYLLNXu2_Bf4-z7K93enOiHVVBZgVXM5ZAMwREgPQwnEfRDDOJ6UBK0Wq1BbBlFVqfZk4n4M1UhqM41IeljXnlHXWcGj2GlkVHCyZAVnd3p0cHS83ddBtJlLVHc5JuNyawQKJh9iynCVcyZyVvy2AsU7A38DtH47ZuN7t3SI3O6BK37SSdZus-PoOud6WrlzcJV9BvujO8dHPb99jhPOnGu5OFyAbjV3MPY1ZGGl3zm9Gff0xhhrgEwztg0Yp5hlHQnqKsSHUIgFcuqB4Om8ogFM6nYwpIFispUTbtNP3yPQqRvw-GdRN7TcIVTykmeFCqsSIwquKc2WCEph1DICiHZIX_djqszZbh45edi51ywkNnNCRE7ockm0c_iUlZtqOD5rzD7pTXF1JaXObo38VwG0SVJ6HQgJQCpUw0sEnN3vm6U79Z_pSWIfk6fI1KC56Y0ztm4uWBuAhTLFDst4yfdkTgVl2AMsOycteCi4b__cPPfh_X56QG6Pp-FAf7k8OHpK1LAplwVK1SQbz8wv_CODVvHrcCTUl-orV6BcyZDj1 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYhLxbOkFDASnMDaJHYS-4AQtKxaSlcVWqS9WY4fgFQlpbsVWk78B34Nf4dfwoyTbIV43HpKlIwcxzNjf_a8CHlc5tIZngZWcSeZKKVhJrM183VqZenK1MVyb4eTcu-9eDMrZmvkxxALg26Vw5wYJ2rXWjwjH6FFQEjMfjcKvVvE0e74xclnhhWk0NI6lNPoROTAL7_A9m3-fH8XeP0kz8evpzt7rK8wwKzgcsEC4I-QGoAZjvsggnE-rQzsWKTKbBlMVWfWV6nzBexMKoM-XcrDEuecss4aDs1eIpcrXmSoYtWsWh3voAFNZKoP00m5HM1hqcRwtrxgKVeyYNVvS2GsGPA3mPuHiTaufOPrZKOHrPRlJ2M3yJpvbpIrXRHL5S3yFSSN7rw7-vnte_R1_tTA3fESpKS1y4WnMR8j7SP-5tQ3H6PTAT5BJz9olGLGcSSkx-glQi0SwKV3j6eLlgJMpdPJIQUsi1WVaJeA-jaZXsR43yHrTdv4u4QqHrLccCFVakTpVc25MkEJzD8GkNEm5Okwtvqky9uho72dS91xQgMndOSErhLyCod_RYk5t-OD9vSD7lVY11LawhZoaQWYmwZVFKGUAJlCLYx08MntgXm6nwjm-lxsE_Jo9RpUGO0ypvHtWUcDQBEm24Rsdkxf9URgvh1AtQl5NkjBeeP__qGt__flIbkKyqPf7k8O7pFreZTJkmVqm6wvTs_8fcBZi_pBlGhK9AVr0C9E0jvF |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+CRP-albumin-lymphocyte+index+provides+enhanced+prognostic+value+in+liver+cancer+compared+to+the+TNM+staging+system&rft.jtitle=Scientific+reports&rft.au=Zhao%2C+Hong&rft.au=Yin%2C+Bing&rft.au=Li%2C+Xiang-Rui&rft.au=Liu%2C+Xiao-Yue&rft.date=2025-06-19&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft.spage=20090&rft_id=info:doi/10.1038%2Fs41598-025-03985-7&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |